BRUNO LUIGI ROCHA FAILLACE
Projetos de Pesquisa
Unidades Organizacionais
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
- Left ventricular pseudoaneurysm associated with systemic lupus erythematosus(2019) HOFF, L. S.; PIMENTEL, C. Q.; FAILLACE, B. L. R.; ROCHITTE, C. E.; DEMARCHI, L. M. M. F.; BONFA, E.; SEGURO, L. P. C.Systemic lupus erythematosus (SLE) is associated with several cardiac manifestations but, to our knowledge, there have been no previously published reports on left ventricular (LV) pseudoaneurysm in this disease. We describe a case of a 30-year-old woman with SLE who presented with a disease flare (acute and subacute cutaneous lupus, pericarditis, fever, leukopenia) associated with heart failure syndrome. The patient was diagnosed with a large LV pseudoaneurysm and a bovine pericardium patch closure was performed. Coronary arteries were angiographically normal, and cardiac magnetic resonance imaging did not exhibit detectable myocardial fibrosis or infarction. Trauma, previous cardiac surgery, Chagas disease, and antiphospholipid syndrome were excluded. Histopathology of the pericardium revealed lymphocytic arteriolitis raising the possibility of an autoimmune-mediated mechanism for this complication. The unequivocal concomitant diagnosis of lupus flare, the exclusion of other causes of pseudoaneurysm and the histopathological finding of arteriolitis in this patient reinforces the hypothesis of lupus-mediated lesion.
conferenceObject Cardiogenic shock after traumatic coronary hematoma(2013) BISELLI, B.; ULHOA, M. B.; FAILLACE, B. L. R.; PINTON, F. A.; ESCALANTE, J. P.; BACAL, F.; ISSA, V. S.; AYUB-FERREIRA, S. M.; LEMOS-NETO, P. A.; BOCCHI, E. A.- Left Main Compression by a Giant Aneurysm of the Left Sinus of Valsalva: An Extremely Rare Reason for Myocardial Infarction and Cardiogenic Shock(2015) FAILLACE, Bruno L. R.; GALON, Micheli Z.; OLIVEIRA, Marcos Danillo P.; PRADO JR., Guy F. A.; TRUFFA, Adriano A. M.; RIBEIRO, Expedito E.; LEMOS, Pedro A.Aneurysms of the sinus of Valsalva are very rare and mostly located in the right coronary sinus. They might course with dyspnea, fatigue, and acute coronary syndromes. We present herein an extremely rare case report of a 61-year-old woman diagnosed with external left main coronary compression by a giant aneurysm of the left sinus of Valsalva, which was successfully managed with percutaneous coronary intervention.
- Four-year clinical follow-up of the first-in-man randomized comparison of a novel sirolimus eluting stent with abluminal biodegradable polymer and ultra-thin strut cobalt-chromium alloy: the INSPIRON-I trial(2015) OLIVEIRA, Marcos Danillo Peixoto; RIBEIRO, Expedito E.; CAMPOS, Carlos M.; RIBEIRO, Henrique B.; FAILLACE, Bruno L. R.; LOPES, Augusto C.; ESPER, Rodrigo B.; MEIRELLES, George X.; PERIN, Marco A.; ABIZAID, Alexandre; LEMOS, Pedro A.Background: The Inspiron (TM) sirolimus-eluting stent (SES) is a low-dose, ultra-thin-strut cobalt-chromium stent abluminally coated with biodegradable polymers (BP). Previous results from the INSPIRON-I trial, a first-in-man study, have proven the efficacy of the novel stent in reducing neointimal proliferation. The present report aims at evaluating the long-term clinical outcomes of patients enrolled into the INSPIRON-I trial (Clinical Trials Gov. identifier: NCT01093391). Methods: A total of 57 patients (60 lesions) were randomly allocated in a 2: 1 ratio to treatment with the Inspiron (TM) SES vs. its equivalent Cronus (TM) bare metal stent (BMS, both by Scitech Medical (TM), Aparecida de Goiania, Goias, Brazil), in four tertiary centers. The primary endpoint of the present analysis was the occurrence of major adverse cardiac events (MACE) [death, myocardial infarction (MI), target vessel revascularization (TVR) and/or target lesion revascularization (TLR)] at 4 years. Results: Baseline clinical and angiographic characteristics of both groups were similar. After 4 years, the primary endpoint occurred in 7.9% vs. 23.5% of patients in Inspiron and control groups respectively (P=0.11). The rate of death/MI was similar between the groups, but there was a significant decrease in the risk of repeat revascularization in the Inspiron group compared to the control arm TLR (0.0% vs. 23.5% respectively, P= 0.02). There were no stent thromboses in the study population. Conclusions: The novel Inspiron (TM) SES showed a sustained safe and effective clinical profile after 4-year of follow-up, with very low adverse events and null stent thrombosis (ST) occurrence.
- Potential of transcatheter aortic valve replacement to improve post-procedure renal function(2017) FAILLACE, Bruno L. R.; RIBEIRO, Henrique B.; CAMPOS, Carlos M.; TRUFFA, Adriano A. M.; BERNARDI, Fernando L.; OLIVEIRA, Marcos D. P.; MARIANI JR., Jose; MARCHINI, Julio F.; TARASOUTCHI, Flavio; LEMOS, Pedro A.Background: Baseline comorbidities including renal dysfunction are frequently found in patients treated with transcatheter aortic valve replacement (TAVR) and may increase the risks of acute kidney injury (AKI), although some of them may actually improve renal function. We aimed to evaluate the potential of TAVR to acutely improve post-procedure renal function. Methods: This is a prospective single-center registry of consecutive patients with severe symptomatic aortic stenosis treated by transfemoral TAVR. Creatinine levels were determined at baseline and daily until hospital discharge. AKI was defined according to VARC-2 criteria. Patients who had improvement of creatinine levels >25% were classified as having TAVR induced renal function improvement (TIRFI). Results: A total of 69 patients undergoing TAVR were included, with a mean age of 83.0 +/- 7.4 years, being 24.6% diabetics, with a median STS score of 9.2 (5.1-21.6). Using the VARC-2 criteria, the majority of patients (64.6%) did not have renal impairment, while AKI was detected in 35.4% of the patients. Importantly, in those with prior severe renal dysfunction (clearance <30 mL/min/1.73 m(2)) or diabetes, AKI reached up to 50% and 56.3% of the patients, respectively. Conversely, acute kidney recovery (TIRFI) occurred in 12 patients (18.5%) being >50% in 1 patient (1.5%), and at hospital discharge the majority of the patients (88.6%) left the hospital in their original or better renal function categories. Conclusion: Despite multiple comorbidities in a selected TAVR-population and the use of contrast media, TAVR did not impair renal function in a majority of patients, with a significant proportion of them rather having acute renal function improvement.